Here, we evaluated the exposure–response of efficacy (cytotoxicity) versus safety (IL6 release) with the integrated analysis in the same high-expressing cell line (MKN45) as previously utilized (19) to ensure the safety of patients with high tumor target expression. Here, IL6 is linked to neoplasm.